Spironolactone metabolites in TOPCAT - New insights into regional variation

New England Journal of Medicine

Volumn 376, Issue 17, 2017, Pages 1690-1692

  De Denus, Simon ^a   O'Meara, Eileen ^a   Desai, Akshay S ^b   Claggett, Brian ^b   Lewis, Eldrin F ^b   Leclair, Grégoire ^c   Jutras, Martin ^c   Lavoie, Joël ^a   Solomon, Scott D ^b   Pitt, Bertram ^d   Pfeffer, Marc A ^b   Rouleau, Jean L ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENONE; DRUG METABOLITE; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ALDOSTERONE BLOOD LEVEL; CANADA; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG RESPONSE; DRUG USE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONALIZATION; RUSSIAN FEDERATION; UNITED STATES; BLOOD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; HEART FAILURE; MEDICATION COMPLIANCE; METABOLISM;

CANADA; CANRENONE; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; MEDICATION ADHERENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RUSSIA; SPIRONOLACTONE; UNITED STATES;

EID: 85018939774     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1612601     Document Type: Letter

References (5)

1. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-92.
2. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
3. Tomaszewski M, White C, Patel P, et al. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100: 855-61.
4. Reilly RF, Jackson EK. Regulation of renal function and vascular volume. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Education, 2011: 671-720.
5. Aldactone. New York: Pfizer, October 2014 (package insert) (http://labeling.pfizer.com/ShowLabeling.aspx?id=520).